

K. Aktories · C. Wilde · M. Vogelsgesang

Rho-modifying C3-like ADP-ribosyltransferases

Published online: 15 September 2004
© Springer-Verlag 2004

Abstract C3-like exoenzymes comprise a family of seven bacterial ADP-ribosyltransferases, which selectively modify RhoA, B, and C at asparagine-41. Crystal structures of C3 exoenzymes are available, allowing novel insights into the structure-function relationships of these exoenzymes. Because ADP-ribosylation specifically inhibits the biological functions of the low-molecular mass GTPases, C3 exoenzymes are established pharmacological tools to study the cellular functions of Rho GTPases. Recent studies, however, indicate that the functional consequences of C3-induced ADP-ribosylation are more complex than previously suggested. In the present review the basic properties of C3 exoenzymes are briefly summarized and new findings are reviewed.

Introduction

Many bacterial ADP-ribosyltransferases are potent bacterial protein toxins and important virulence factors. After cellular uptake caused by highly efficient cell entry mechanisms, they modify eukaryotic target proteins with great specificity and often grossly affect biological functions of their targets. These properties of the toxins are the reason for their use as cell biological and pharmacological tools (Aktories 2000). Particularly successful pharmacological tools are ADP-ribosyltransferases of the C3 family, which modify Rho GTPases. In the 1990s, C3 exoenzymes turned out to be very valuable experimental keys to understand the wide array of diverse regulatory functions of Rho GTPases. In hundreds of papers, C3 exoenzymes have been widely employed as cell biological tools to elucidate the cellular functions of Rho GTPases. This holds true despite the fact that these ADP-ribosyltransferases are rather poorly taken up by eukaryotic target cells and their roles as virulence factors are still not well defined. Here, we will briefly review the basic properties of these ADP-ribosyltransferases and will focus on novel findings on the functional consequences of C3-induced ADP-ribosylation and discuss recent reports on the structure and function of the enzymes.

K. Aktories (✉) · C. Wilde · M. Vogelsgesang
Institute of Experimental and Clinical Pharmacology and Toxicology,
Albert-Ludwigs University Freiburg, Otto-Krayer-Haus, Albertstr. 25, Freiburg, Germany

Recent reviews about C3 exoenzymes focused on different aspects of the transferases (Aktories et al. 1992; Aktories 1997a,b; Boquet et al. 1998; Just et al. 2001; Narumiya and Morii 1993; Wilde and Aktories 2001). The exciting follow-up of the initial major discoveries in the field of Rho GTPases, including the role of C3 in this process, was recently vividly communicated by Ridley and Hall (Ridley and Hall 2004).

Sources of C3-like ADP-ribosyltransferases

C3 exoenzymes are produced by different types of Gram-positive obligate and facultative pathogens. So far, seven C3-like isoforms have been described, which are produced by *Clostridium botulinum*, *Clostridium limosum*, *Bacillus cereus* and *Staphylococcus aureus*. C3 was first identified as a product of *Clostridium botulinum* types C and D (Aktories et al. 1987, 1988; Rubin et al. 1988). Later it was found that two isoforms are produced by these Clostridia, which are about 65% identical in their amino acid sequences (Nemoto et al. 1991). They have been termed C3bot1 and C3bot2. At least the gene for C3bot1 is located on the same phage, which also encodes *C. botulinum* neurotoxins type C (Popoff et al. 1990). C3lim is produced by *Clostridium limosum* (Just et al. 1992) and is about 63% identical with C3bot1. *Bacillus cereus* produces C3cer (Just et al. 1995a), which is about 30% identical with C3bot1. Three C3 isoforms have been described, which are produced by *Staphylococcus aureus* (C3stau1, 2, and 3). These exoenzymes are about 35% identical with C3bot1 and 66%–77% identical between each other. The C3stau exoenzymes are also termed EDINs (Epidermal differentiation inhibitor) (Inoue et al. 1991; Wilde et al. 2001b; Yamaguchi et al. 2001) (Fig. 1a, b).

Structure–function analysis of C3-like exoenzymes

C3-like ADP-ribosyltransferases are enzymes of about 25 kDa, which all share the same activity in the sense that they mono-ADP-ribosylate RhoA, B, and C at the same site at asparagine 41 (Aktories et al. 1989; Braun et al. 1989; Chardin et al. 1989; Just et al. 1992, 1995a; Quilliam et al. 1989; Sekine et al. 1989; Sugai et al. 1992; Wilde et al. 2001b). The bacterial exoenzymes possess no receptor-binding or translocation domain and, consist exclusively of the catalytic domain, which possess ADP-ribosyltransferase and like many other ADP-ribosyltransferases also NAD glycohydrolase activity (Fig. 1a). Most important for understanding of the structure-function-relationship of C3-like transferases were the analysis of the crystal structures of C3bot either bound or unbound to NAD (Han et al. 2001; Ménétrey et al. 2002). These studies showed that the exoenzymes are very similar in structure and folding and share almost all functionally pivotal residues despite the limited primary sequence homology (some are not more than ~30% identical in their amino acid sequences). These data also corroborated previous mutational analysis, which let to the identification of many functionally important residues and their possible role in the ADP-ribosylation reaction (Böhmer et al. 1996; Just et al. 1995a; Saito et al. 1995; Wilde et al. 2002b).

The active site of C3bot (and most likely of other C3-like ADP-ribosyltransferases) consists of a mixed α/β -fold with a β -sandwich core, consisting of a five-stranded mixed β -sheet perpendicularly packed against a three-stranded antiparallel β -sheet. Four consecutive α -helices surround the three stranded β -sheet. An additional α -helix flanks the five-







Fig. 1 Structure of C3 transferase. **a** Scheme of the primary sequence of C3bot showing the catalytic glutamate, residues of the ADP-ribosylation toxin-turn-turn (ARTT) loop, which is involved in protein substrate recognition, and PN-loop, which is involved in binding of phosphates of NAD. The STS-motif, which is conserved within the family of ADP-ribosyltransferases (C3stau isoforms possess an STQ motif), and several arginine residues involved in interaction with NAD are shown. **b** The sequences of the seven C3-like ADP-ribosyltransferases are given. *Clostridium botulinum* C3 transferase type I (C3bot1; Acc.Nr. P15879), *Clostridium botulinum* C3 transferase type II (C3bot2; Acc.Nr. Q00901), *Clostridium limosum* C3 transferase (C3lim; Acc.Nr. Q46134), *Bacillus cereus* C3 transferase (C3cer; Acc.Nr. AJ429241.1), *Staphylococcus aureus* C3 transferase A, B, and C (C3stau1; Acc.Nr. P24121; C3stau2; Acc.Nr. BAC22946, C3stau3; Acc.Nr. NP_478345 ; also termed EDIN A,B,C).

stranded sheet (Han et al. 2001). After binding of NAD, a clasping movement (“Crab-claw” movement) of the transferase occurs which involves the structural elements $\alpha 5$, $\beta 2$, $\beta 7$ and $\beta 8$, and $\alpha 3$ to enclose the substrate (Evans et al. 2003; Ménétrey et al. 2002) (Fig. 2). A novel structural motif, termed “ADP-ribosylating-toxin-turn-motif” (ARTT-motif) was proposed to be involved in the ADP-ribosylation reaction and suggested to be typical for all Rho-modifying C3-like transferases and also for the structurally related actin-modifying ADP-ribosyltransferases like *Clostridium botulinum* C2 toxin (Han and Tainer 2002). In C3bot, this motif consists of residues 167–170 (note that the counting is



without the signal sequence of 40 residues) for “turn 1” and residues 171–174 for “turn 2” (Figs. 1a, b, 2a). Turn 1 contains a conserved aromatic residue (C3bot^{Phe169}). The aromatic side chain points to the surface of the molecule and was suggested to recognize the substrate RhoA via hydrophobic patches around the acceptor amino acid residue Rho Asn41. The exchange of this critical residue to alanine or lysine in C3stau2 leads to a decreased binding of RhoA and abolishes the ADP-ribosyltransferase activity of these mutants (Wilde et al. 2002b). In the second turn, two residues (C3bot^{Gln172} and C3bot^{Glu174}) play important roles in enzyme activity. The side chain of C3bot^{Gln172} forms hydrogen bonds with the O2'-hydroxyl of the nicotinamide ribose (Fig. 1b), and is thought to be involved in the positioning of the ternary C3-NAD-Rho complex on turn 2. The side chain of C3bot^{Glu174} stabilizes the formation of an oxocarbenium transition state that arises during the enzymatic reaction (Han et al. 2001; Ménétrey et al. 2002; Oppenheimer 1994) (Fig. 2c). Exchange of either of these glutamine or glutamate residues to any other amino acids results in inhibition of the asparagine-modifying ADP-ribosyltransferase activity (Böhmer et al. 1996; Evans et al. 2003; Ménétrey et al. 2002; Saito et al. 1995; Wilde et al. 2002b).

Recently, it was reported that the ARTT-motif of C3bot undergoes conformational changes upon NAD-binding. While NAD is bound to C3bot, the complete motif is orientated into the inside of the protein and participates in NAD binding (Ménétrey et al. 2002). This form of NAD-binding was also observed in other ADP-ribosyltransferases (Bell and Eisenberg 1996; Choe et al. 1992; Han et al. 1999; Li et al. 1996). In C3stau2, the resting (NAD free) position of the ARTT loop is similar to the NAD bound state in C3bot. C3 exoenzymes produced by *S. aureus* are unique as compared to the other C3 transferases, because the loop before the ARTT loop possesses an additional two residues. These two residues are suggested to be responsible for positioning the ARTT loop of C3stau isoforms in a conformation identical not to that of the NAD-free C3bot1 structure but to that of the C3bot1-NAD-bound conformation. Therefore, conformational changes subsequent to NAD binding are minor in this region (Evans et al. 2003).

Deduced from the crystal structure of C3bot bound to NAD, a further structural element, termed phosphate-nicotinamide-loop (PN-loop), was suggested to be involved in NAD-binding (Fig. 1b). It covers residues C3bot 137–146 and is also located between strands $\beta 3$ – $\beta 4$. At least one critical arginine within this loop is conserved in all C3-like ADP-ribosyltransferases. It was reported that this residue forms hydrogen bonds to the phosphate groups of NAD (Fig. 1b). Consequently, exchange to aspartate in C3bot or C3cer abolished both NAD glycohydrolase activity and ADP-ribosyltransferase activity of this mutant (Ménétrey et al. 2002; Wilde et al. 2003).

Enzyme activity and substrate specificity

Like typical ADP-ribosyltransferases, C3 exoenzymes split NAD into ADP-ribose and nicotinamide and transfer the ADP-ribose moiety onto Rho protein (Fig. 3). C3 modifies

Fig. 2 Structure of C3bot. **a** The crystal structure of C3bot shows the ADP-ribosylation toxin-turn-turn (ARTT) motif. This motif is suggested to be involved in the interaction with the protein substrate, e.g., RhoA (C3 was designed by Swiss-Pdb Viewer 3.7 (database code 1G24). The insert exhibits the putative interaction of C3stau with RhoA. Data are from Han et al. (Han et al. 2001). **b** Scheme of the folding of C3bot (see text). **c** Residues, which participate in the binding of NAD to C3bot. Note that the counting of residues is without the signal sequence.




Fig. 3 ADP-Ribosylation of RhoA by C3. C3 transferases ADP-ribosylate RhoA at position Asn41. The acceptor amino acid is located in or very close to the so-called effector region (switch I-region) of RhoA. Rho structure was designed by Rasmol version 2.7.2 (database code 1FTN).

asparagine residue (Asn41) of the target protein (Sekine et al. 1989). This is unique for this family of ADP-ribosyltransferases. Many bacterial ADP-ribosyltransferases modify arginine residues, including cholera toxin, *Pseudomonas exoenzyme S* and *T*, and the actin modifying binary ADP-ribosyltransferases like *C. botulinum C2* toxin. Cysteine is modified by pertussis toxin (Aktories 2000; Barbieri et al. 2002).

C3-like ADP-ribosyltransferases are characterized by their substrate specificity, because they modify preferentially Rho A, B, and C. Other Rho GTPases are poor substrates, including Rac and Cdc42. Recently, it was reported that the transferases C3stau1 and C3stau2 (EDIN A and EDIN B) from *S. aureus* ADP-ribosylate also RhoE and Rnd3. RhoE and Rnd3 are isoforms, identical except for a 15-residue N-terminal extension on Rnd3, that are antagonistic to RhoA (Guasch et al. 1998; Foster et al. 1996; Nobes et al. 1998; Riento et al. 2003). They bind GTP but lack GTPase activity. However, the kinetics of the modification of RhoE/Rnd3 is much more slower than that to modify RhoA (Wilde et al. 2001b).

The targets of C3 exoenzymes are molecular switches

RhoA, B, and C, the main targets of C3 exoenzymes, belong to the Rho subfamily of low molecular mass GTP-binding proteins, which comprises more than twenty related GTP-binding proteins, including RhoA, B, C, Rac1, 2, 3, Cdc42, RhoD, Rnd1, Rnd2 (RhoN), RhoE/Rnd3, RhoF (Rif), RhoG, RhoH (TTF) and TC10, TCL, Chp, and Wrch (Jaffe and Hall 2002; Nagata et al. 1998; Ridley 2000; Wennerberg and Der 2004). Most of them, e.g., the prototypes RhoA, B, C, Rac, and Cdc42 cycle between an activated GTP-bound form and an inactive GDP-bound form (Fig. 4). The exchange is tightly controlled by regulating proteins: (a) guanine nucleotide exchange factors (GEFs; more than 60 have been identified) which activate Rho by promoting the exchange of GDP to GTP, (b) GTPase-




Fig. 4 RhoA GTPase cycle. Rho GTPases are inactive in the GDP bound form and activated by GDP/GTP exchange, which is facilitated by guanine nucleotide exchange factors (*GEFs*). In the active form RhoA interacts with a large array of effectors to induce various cellular effects indicated. The active form of RhoA is terminated by hydrolysis of the bound GTP, which is facilitated by GTPase-activating proteins (*GAPs*). The inactive form is extracted from the membrane by guanine nucleotide dissociation inhibitor (*GDI*), which keep the Rho GTPases in their inactive form in the cytosol.

activating proteins (*GAPs*; more than 70 have been identified), which inactivate Rho proteins by increasing their intrinsic rate of GTP-hydrolysis, and (c) guanine nucleotide dissociation inhibitors (*GDI*s; only three are known), which sequester the isoprenylated Rho proteins in the cytosol. The active GTP-bound form of Rho GTPases, which is mostly located at the cell membrane, interacts with multiple cellular effectors, including different protein kinases, lipid kinases, phospholipases and a still growing number of adaptor proteins, involved in a large array of distinct cellular functions, including regulation of the cytoskeleton (Burridge and Wennerberg 2004), cell and smooth muscle contraction, phagocytosis, polarity, activation of transcription, cell cycle progression, and cell transformation (Bishop and Hall 2000; Etienne-Manneville and Hall 2002; Jaffe and Hall 2002; Wennerberg and Der 2004).

Rho GTPases have been identified to be the preferred target of several other bacterial toxins and effectors. They can be activated by deamidation (*E. coli* cytotoxic necrotizing factors, CNF1, CNF2, and CNFy) (Flatau et al. 1997; Hoffmann et al. 2004; Schmidt et al. 1997) and by transglutamination (*Bordetella* dermonecrotizing toxin DNT) (Masuda et al. 2000) at Gln63/61 in Rho and Rac/Cdc42, respectively. Moreover, Rho GTPases are activated by *Salmonella* SopEs, which possess GEF activity and mimic the regulatory functions of endogenous activators (Hardt et al. 1998). An inactivation of Rho GTPases is caused by mono-O-glucosylation by the large clostridial cytotoxins, including toxins A and B of *Clostridium difficile* (Just et al. 1995b), lethal toxin from *Clostridium sordellii* (Just et al. 1996), and α -toxin from *Clostridium novyi* (Selzer et al. 1996). *Yersinia* YopE (von Pawel-Rammingen et al. 2000), *Salmonella* SptP (Fu and Galán 1999), or *Pseudomonas aeruginosa* ExoS (Goehring et al. 1999) inactivate Rho GTPases by mimicking en-

ogenous GAP activity. Moreover, it has been shown recently that *Yersinia* YopT acts as a protease, which cleaves Rho-GTPases at the C-terminal isoprenylated cysteine to inactivate the GTPase (Shao et al. 2002, 2003).

Functional consequences of the ADP-ribosylation of Rho

The ADP-ribosylation of RhoA (B, C) occurs at asparagine-41 (Sekine et al. 1989), which is part of or at least located in close vicinity to the switch-1 region (residues 28–40/41) of the GTPase (Fig. 3). The modification renders Rho biologically inactive (Paterson et al. 1990). The switch-1 region adopts different conformations depending on the nucleotide bound to the GTPase and is the molecular basis for the conduction of signals downstream. The inactivation of Rho by C3 exoenzyme-catalyzed ADP-ribosylation can be easily monitored by redistribution of actin filaments and depolymerization of stress fibers (Chardin et al. 1989; Paterson et al. 1990; Wiegers et al. 1991). ADP-ribosylation of Rho has only minor effects on the nucleotide binding, intrinsic, and GAP-stimulated GTP hydrolase activity. Also binding of ADP-ribosylated Rho with effector proteins, e.g., protein kinase N or Rho kinase (Sehr et al. 1998) and phospholipase D (Genth et al. 2003b) is possible (Fig. 5). Moreover, ADP-ribosylated RhoA is still able to activate its effectors (Genth et al. 2003a). However, this activation appears to depend on the fact that it is already in the active form before ADP-ribosylation. ADP-ribosylation appears to prevent the conformational changes occurring with activation of Rho proteins (Genth et al. 2003b). In line with this notion is the finding that activation of ADP-ribosylated Rho by GEFs (e.g., Lbc) is inhibited (Sehr et al. 1998) (Fig. 5b). Importantly, ADP-ribosylated RhoA seems to be trapped in the Rho/GDI-complex (Genth et al. 2003a). This was studied with a simple membrane filtration assay. The unmodified RhoA/GDI complex (mass ~45 kDa) is not able to pass a 30-kDa cut-off membrane filter. In the presence of phosphatidylinositol 4,5-bisphosphate (PIP₂), the complex dissociates and releases RhoA (~20 kDa) and GDI (~24 kDa), which are able to pass the membrane filter. After ADP-ribosylation, however, PIP₂ is not able to dissociate the RhoA/GDI-complex, indicating a tight interaction after modification of Asn41 by C3 (Fig. 5c). In line with the apparent increase in the affinity between modified RhoA and GDI, ADP-ribosylated RhoA is exclusively found in the cytosolic fraction of C3-treated cells. ADP-ribosylation reduces the binding of RhoA to membranes (Fujihara et al. 1997; Genth et al. 2003a). Taken together, inhibition of activation of ADP-ribosylated Rho by GEFs and sequestration of ADP-ribosylated RhoA in the GDI-complex are most likely the causes of C3-induced blockade of Rho-dependent signaling (Fig. 6).

Nonenzymatic actions of C3 exoenzymes

Recently, it was reported that C3-like exoenzymes interact directly with other small GTP-binding proteins not belonging to the Rho subfamily of GTPases. Wilde and coworkers showed that C3 exoenzymes from *C. botulinum* and *C. limosum* bind with high affinity (K_D ~10 nM, for *C. limosum*) to RalA (Wilde et al. 2002a) without modifying the GTPase by ADP-ribosylation. Ral is a member of the Ras subfamily of small GTPases and occurs in two isoforms, RalA and B, which share ~35% amino acid identity to RhoA. Ral has been implicated in several cellular processes, e.g., Ras-mediated cell transformation (Feig




Fig. 5 Functional consequences of ADP-ribosylation of RhoA. **a** ADP-ribosylation of RhoA at Asn41 has no major effect on the interaction of the GTPase with the RhoA effector protein kinase N (*PKN*). Under control conditions, only the active GTP-form (here the GTP γ S-form) but not the inactive GDP-form of RhoA is precipitated by the Rho-binding domain (*RBD*) of protein kinase N (*PKN*). In the experiment shown, this *RBD*-domain was coupled to Sepharose beads and used for precipitation. After ADP-ribosylation, which can be monitored by the shift of RhoA to an apparent higher molecular mass, RhoA is still able to interact with *PKN* (data from Sehr et al. 1998). **b** ADP-ribosylation decreases the rate of activation by the GEF protein LBC. The activation of RhoA was followed by the release of the fluorescently labeled mantGDP from RhoA to allow binding of GTP. Therefore, activation of RhoA causes decrease in fluorescence. Pretreatment of RhoA with C3 reduces the rate of RhoA activation (data from Sehr et al. 1998). **c** ADP-ribosylation increases the binding of RhoA to GDI. In the cytosol, Rho is in a complex with GDI. Therefore, only the complex is detected by gel or membrane filtration. Under control conditions phosphatidylinositol bisphosphate (*PIP*₂) causes dissociation of this complex. Accordingly, Rho released from the complex is detected. After ADP-ribosylation *PIP*₂ is not able to induce dissociation of the complex. Therefore, ADP-ribosylated Rho stays in the cytosol in a complex with GDI. (Data from Genth et al. 2003a).





Fig. 6 Summary of the functional consequences of the ADP-ribosylation of RhoA by C3. RhoA is ADP-ribosylated by C3 in the GDI-free form. 1 ADP-Ribosylation inhibits the activation of RhoA by GEF. 2 ADP-ribosylated Rho is still able to interact at least with some effectors such as kinases. 3 The nucleotide binding and the GTP hydrolysis is almost not affected by ADP-ribosylation. 4 ADP-ribosylation decreases membrane-binding of RhoA. 5 Binding of ADP-ribosylated RhoA to GDI is increased. Therefore, ADP-ribosylated RhoA will remain in the inactive form in the cytosol.

et al. 1996; Urano et al. 1996), cytoskeleton rearrangement (Jullien-Flores et al. 1995; Ohta et al. 1999; Park and Weinberg 1995), and vesicle trafficking, e.g., by regulating the exocyst via binding to sec5 (Moskalenko et al. 2001). Ral acts on phospholipase D1 (PLD1) (Jiang et al. 1995; Luo et al. 1998) and it is suggested that both RalA and PLD1 modulate receptor endocytosis and vesicle transport. Binding of C3 to RalA inhibits its ADP-ribosyltransferase activity to modify RhoA (Fig. 7). Similarly, interaction of C3 with RalA reduces the ability of the GTPase to activate PLD1 in vitro, suggesting that the binding of the exoenzyme to Ral occurs in a region of the GTPase, which is important for the interaction with its effectors. Moreover, interaction of C3 with Ral prevents glucosylation of Ral by *Clostridium sordellii* lethal toxin in intact cells (Wilde et al. 2002a). Because glucosylation of Ral occurs in the functionally important switch-1 region, it is likely that interaction of C3 with this region also affects Ral functions in intact cells. Such a sequestration of Ral might be relevant at high concentration of C3, which can be achieved by microinjection or overexpression of C3 (see below). In contrast to the exoenzymes from *C. botulinum*, *C. limosum*, and *B. cereus*, the transferase C3stau2 from *S. aureus* is not capable of binding to RalA.

Recently another C3 effect, which is independent of the ADP-ribosyltransferase activity has been reported. It is well-known that Rho proteins regulate neurite outgrowth (see below). Several studies showed that C3 prevent neurite retraction induced by activated RhoA (see below). Surprisingly, Ahnert-Hilger and coworkers found that C3bot but not other C3 exoenzymes promote the axonal growth and branching independent of the enzyme activity (Ahnert-Hilger et al. 2004). Moreover, this effect depended on the extracellular application of the exoenzyme. Intracellularly expressed C3bot did not induce axon growth. They propose a novel neurotrophic function of C3bot independent of its transferase activity.

Fig. 7 Ral protein inhibits C3-induced ADP-ribosylation of RhoA. **a** RhoA was ADP-ribosylated by C3 with [32 P]NAD in the presence of various small GTPases (Rac, Cdc42, Ras, Rap, and Ral). Only Ral inhibited the ADP-ribosylation of RhoA. **b** Time course of ADP-ribosylation of RhoA in the presence and absence of Ral. Ral caused an immediate inhibition of the modification of RhoA. (Data from Wilde et al. 2002a).



Pathophysiological role of C3

Although much is known about the cellular functions of Rho GTPases, the roles of C3-like transferases in pathogenicity are not at all understood (Fig. 8). An action of C3 exoenzymes on the immune system of the eukaryotic target organism is most likely. Some of these effects have been already mentioned. Inhibition of immune cell functions including cytotoxicity of lymphocytes (Lang et al. 1992), adhesion (Nemoto et al. 1996), migration and invasion of lymphocytes (Stam et al. 1998; Verschueren et al. 1997), and leukocytes (Laudanna et al. 1996, 1997) by C3bot have been demonstrated. Rho GTPases have been proven to be important components of signal pathways used by antigen receptors, cytokine, and chemotaxins receptors to regulate the immune response (Heath and Holifield 1991; Henning and Cantrell 1998; Laudanna et al. 1996; Prepens et al. 1996; Price et al. 1995; Wojciak-Stothard et al. 1998). Moreover, Rho proteins participate in the barrier functions of epithelial cells (Nusrat et al. 1995; Vouret-Craviari et al. 1998) and in wound healing (Santos et al. 1997). However, considering the poor cell accessibility of C3 exoenzymes, an important question remains: how do these specific and potent agents get to their site of action? At least two possibilities are feasible. Recently, it was shown that pore-forming toxins appear to act as a delivery system for bacterial proteins. Madden and coworkers (Madden et al. 2001) reported that *Streptococcus pyogenes* uses streptolysin O, a cholesterol-dependent cytolysin, to translocate *S. pyogenes* NAD-glycohydrolase SPN into the target cells. This method of target-specific translocation appears to be comparable with the type-III secretion system frequently found in gram negative bacteria. Considering the fact that many of the bacteria, which synthesize C3 exoenzymes, also produce pore-forming agents, it is feasible that a similar mechanism is functional with these pathogens.

Fig. 8 The role of C3 as a virulence factor is not clear. However, Rho GTPases (including other members of the family) have been shown to be involved in several processes, which are important for innate and acquired immunity, including adhesion invasion and endocytosis of immune cells, migration, superoxide anion production (at least true for Rac), interaction of T-cells with antigen-presenting cells (*APC*), cytokine production, and epithelial permeability (see also Table 1).

Role of C3 as a virulence factor?

Rho GTPases are involved in innate and acquired immunity

1. Adherence
2. Invasion and Endocytosis
3. Phagocytosis
4. Migration
5. O₂⁻-Production
6. T-cell : APC interaction
7. Cytokine production
8. Epithelial permeability

The other possibility is based on recent findings that more pathogens than previously suggested are capable of invading host cells. This also applies to *Staphylococci* (Lowy 2000; Mempel et al. 2002). Moreover, it was suggested that the pathogens enter the cytosol of target cells (Bayles et al. 1998). This implies that the bacterium is able to release the Rho-ADP-ribosylating enzyme directly into the cytosol, where its protein target is localized (Wilde et al. 2001a; G.S. Chhatwal et al., unpublished data).

C3-like exoenzymes as pharmacological tools

Because C3-like ADP-ribosyltransferases are highly specific for Rho GTPases, they are established pharmacological and cell biological tools to study the physiological functions of Rho GTPases. On the other hand, C3-like ADP-ribosyltransferases lack a specific receptor binding and translocation domain and, therefore, their cellular uptake is rather poor. Due to this fact, the toxins have to be applied in high concentrations and/or for long incubation periods. Quite often the toxins were introduced into target cells by microinjection (Paterson et al. 1990; Watanabe et al. 1997). Another approach to overcome this problem is the use of C3-toxin chimeras. Aullo et al. (Aullo et al. 1993) fused C3bot to diphtheria toxin. DC3B, a fusion protein of C3 and the binding and translocation domain of diphtheria toxin, has a high affinity for the DT receptor, but apparently enters the target cell by a mechanism different from the typical pathway of diphtheria toxin. Because the action of this fusion toxin is limited to cells with receptors for diphtheria toxin, other chimeras were constructed. Very efficient is a fusion toxin, which is based on the binary C2 toxin from *Clostridium botulinum*. C2 toxin consists of the actin-ADP-ribosylating enzyme component C2I and the binding and translocation component C2II, which are both separated proteins (Aktories et al. 1986; Barth et al. 2002; Ohishi et al. 1980). After proteolytic activation of C2II, the activated C2II monomers oligomerize to heptamers (Barth et al. 2000) and upon binding of C2I to C2II, both components are internalized by receptor-mediated endocytosis. The N-terminal part (C2IN) of C2I, which alone is sufficient for the interaction with the binding component C2II, was fused to full-length ADP-ribosyltransferases C3lim or C3stau, respectively (Barth et al. 1998; Wilde et al. 2001b). This chimeric toxin increases the potency of C3 several hundred-fold (Meyer et al. 2000; Valderrama et al. 2000; Vischer et al. 2000; Wahl et al. 2000). Because the binding component of C2 toxin

appears to bind to complex and/or hybrid carbohydrates present on all vertebrate cells (Eckhardt et al. 2000), all these cells are sensitive towards the fusion toxin. Also the adaptor domain of the enzyme component and the binding component of iota toxin, which are similar to C2 toxin, have been effectively used for delivery of C3-like toxins into cells (Marvaud et al. 2002).

Recently, it was reported that C3bot could be transported into cells by adding short peptides to the C-terminal end of the exoenzyme. For this purpose short sequence of the human immunodeficiency virus transcription activator Tat was used (Park et al. 2003; Sauzeau et al. 2001). The transport of C3bot into cells can also be accomplished by fusing the third helix of the *Antennapedia* homeodomain protein from *Drosophila* to C3bot. In addition, short proline-rich peptides and highly basic arginine-rich peptides were C-terminally fused to C3 exoenzyme to facilitate the uptake of the transferase (Winton et al. 2002).

Another method to use C3-specific inhibition of Rho GTPases is the intracellular expression of the gene (Hilal-Dandan et al. 2004). Transgenes based on the thymocyte-specific Ick promoter have been used for expression of C3 in thymus. Transgenic mice showed maturational, proliferative, and cell survival defects during T-cell development (Henning et al. 1997). Recently, a transgenic mouse model expressing C3 exoenzyme in a lens-specific manner was utilized (Maddala et al. 2004). Under transcriptional control of the lens-specific alphaA-crystallin promoter mice, expressing the C3 exoenzyme transgene, exhibited selective ocular defects, including cataract and microphthalmia (Rao et al. 2002).

In the following paragraph, cell biological effects, which are observed with the “C3 tool,” are briefly summarized. Quite early studies showed that treatment of Vero cells with C3bot induces morphological changes characterized by rounding up of the cells with concomitant destruction of stress fibers (Chardin et al. 1989). The same findings were obtained with many other cell types and with different C3-like ADP-ribosyltransferases. Many of the classical studies on the functions of Rho GTPases performed in the laboratory of Alan Halls depended on the usage of C3 (Paterson et al. 1990; Ridley et al. 1992; Ridley and Hall 1992).

After C3 treatment, actin-staining by rhodamine-phalloidin usually reveals loss of stress fibers; treated cells remain in contact via small extensions. After removal of toxin from the medium, cells are still viable and the phenotype reverses after a few hours to days by neosynthesis of Rho (Barth et al. 1999). The reversal appears to be especially fast with the C3–C2I fusion toxin, which appears to be degraded rapidly (Barth et al. 1999). In many studies, C3 was shown to prevent the formation of stress fibers and focal adhesions induced by growth factor (Hall 1994; Mackay et al. 1997; Ridley and Hall 1992) or by integrins (Barry et al. 1997). In contrast, processes that are mediated by Rac or Cdc42, like lamellipodia and microspike formation in fibroblasts, are not affected by C3 (Kozma et al. 1995; Nobes and Hall 1995; Ridley and Hall 1992). Although C3bot induces rounding up in adherent cells, the toxins cause cell spreading in monocytes (Aepfelbacher et al. 1996) and in T cells (Borroto et al. 2000).

C3bot was frequently used as a tool to study the role of Rho in cell motility, migration and cell invasion (see Table 1). The exoenzyme was successfully applied in studies on the regulatory function of Rho GTPases in neurite outgrowth, branching, and neuroregeneration. Similarly the role of Rho GTPases in the control of phospholipase D and in phospholipid metabolism was studied with C3. The role of Rho GTPases in transcriptional activa-

Table 1 List of studies with C3 exoenzymes applied as cell biological and pharmacological tools

Rho in regulation of the actin cytoskeleton	Barry et al. 1997; Kozma et al. 1995; Nobes and Hall 1995; Ridley et al. 1992; Ridley and Hall 1992; Wieggers et al. 1991; Wilde et al. 2001b
Rho in cell adhesion, migration, chemotaxis and invasion	Adachi et al. 2001; Anderson et al. 2000; Kusama et al. 2001; Nguyen et al. 2002; Saurin et al. 2002; Strey et al. 2002; Takaishi et al. 1994; Worthylake et al. 2001; Yoshioka et al. 1998
Rho in cell cycle progression, cell division and cytokinesis	Eda et al. 2001; Fiorentini et al. 1998; Kato et al. 2001; Liberto et al. 2002; O'Connell et al. 1999; Olson et al. 1995; Takaishi et al. 1995
Rho and neurite growth	Dergham et al. 2002; Grunwald and Klein 2002; Jalink et al. 1994; Lehmann et al. 1999; Neumann et al. 2002; Niederost et al. 2002; Nishiki et al. 1990; Tigyi et al. 1996; Wahl et al. 2000; Yuan et al. 2003
Rho in endocytic and exocytic processes	Caron and Hall 1998; Doussau et al. 2000; Lamaze et al. 1996; Park et al. 2003; Schmalzing et al. 1995; Vögler et al. 1999
Rho, phospholipase D and phospholipid metabolism	Balboa and Insel 1995; Chong et al. 1994; Kanumilli et al. 2002; Kuribara et al. 1995; Meacci et al. 1999; Ren et al. 1996; Schmidt et al. 1996; Schmidt et al. 1999; Weernink et al. 2000; Xie et al. 2002
Rho and transcription and differentiation	Alberts et al. 1998; Chen et al. 2002; Dreikhausen et al. 2001; Hill et al. 1995; Lu et al. 2001; Mack et al. 2001; Sahai et al. 1998; Sotiropoulos et al. 1999; Su et al. 2001; Takemoto et al. 2002
Rho in signal transduction by heptahelical receptors	Buhl et al. 1995; Fromm et al. 1997; Gohla et al. 2000; Klages et al. 1999; Le Page et al. 2003; Mao et al. 1998a; 1998b; Nguyen et al. 2002; Ohmori et al. 2001; Sagi et al. 2001; Sah et al. 1996, 2000; Xie et al. 2002; Yamakawa et al. 2000
Rho and apoptosis	Bobak 1999; Dubreuil et al. 2003; Fiorentini et al. 1998; Hippenstiel et al. 2002; Mills et al. 1998; Reuveny et al. 2004

tion was another important topic, which was frequently addressed with C3 as a tool. Moreover, C3 was successfully employed in delineation of the role of Rho in the signaling of various heptahelical receptors to the actin cytoskeleton, phospholipases, and the nucleus via heterotrimeric G proteins. Especially important was C3 in studies on the functions of $G\alpha_{12/13}$. Finally, C3 was studied in cell division and apoptosis (for references see Table 1).

Conclusion

Our information about C3 ADP-ribosyltransferases, their structures and mode of actions has increased enormously in recent years. We do understand a lot about the functional consequences of the ADP-ribosylation of Rho GTPases, when C3 is applied as a tool. However, additional potentially important functions and properties of C3 have been described recently, which are not clearly defined or not really understood at present, including the high affinity interaction with Ral and the action as a neurotrophic factor. Moreover, many open questions remain concerning the pathogenic role of C3 exoenzymes. With respect to further progress in the structure function analysis, it would be of major importance to solve the crystal structure of C3 in the complex with its Rho substrate. Hopefully, we will get this information in the near future.

References

- Adachi T, Vita R, Sannohe S, Stafford S, Alam R, Kayaba H, Chihara J (2001) The functional role of rho and rho-associated coiled-coil forming protein kinase in eotaxin signaling of eosinophils. *J Immunol* 167:4609–4615

- Aepfelbacher M, Essler M, Huber E, Czech A, Weber PC (1996) Rho is a negative regulator of human monocyte spreading. *J Immunol* 157:5070–5075
- Ahnert-Hilger G, Holtje M, Grosse G, Pickert G, Mucke C, Nixdorf-Bergweiler B, Boquet P, Hofmann F, Just I (2004) Differential effects of Rho GTPases on axonal and dendritic development in hippocampal neurones. *J Neurochem* 90:9–18
- Aktories K (1997a) Bacterial toxins that target Rho proteins. *J Clin Invest* 99:827–829
- Aktories K (1997b) Rho proteins: targets for bacterial toxins. *Trends Microbiol* 5:282–288
- Aktories K (2000) Bacterial protein toxins as tools in cell biology and pharmacology. In: Cossart P, Boquet P, Normark S, Rappuoli R (eds) *Cellular microbiology*. ASM Press, Washington, pp221–237
- Aktories K, Bärmann M, Ohishi I, Tsuyama S, Jakobs KH, Habermann E (1986) Botulinum C2 toxin ADP-ribosylates actin. *Nature* 322:390–392
- Aktories K, Weller U, Chhatwal GS (1987) Clostridium botulinum type C produces a novel ADP-ribosyltransferase distinct from botulinum C2 toxin. *FEBS Lett* 212:109–113
- Aktories K, Rösener S, Blaschke U, Chhatwal GS (1988) Botulinum ADP-ribosyltransferase C3. Purification of the enzyme and characterization of the ADP-ribosylation reaction in platelet membranes. *Eur J Biochem* 172:445–450
- Aktories K, Braun U, Rösener S, Just I, Hall A (1989) The rho gene product expressed in *E. coli* is a substrate of botulinum ADP-ribosyltransferase C3. *Biochem Biophys Res Commun* 158:209–213
- Aktories K, Mohr C, Koch G (1992) Clostridium botulinum C3 ADP-ribosyltransferase. *Curr Top Microbiol Immunol* 175:115–131
- Alberts AS, Geneste O, Treisman R (1998) Activation of SRF-regulated chromosomal templates by Rho-family GTPases requires a signal that also induces H4 hyperacetylation. *Cell* 92:475–487
- Anderson SI, Hotchin NA, Nash GB (2000) Role of the cytoskeleton in rapid activation of CD11b/CD18 function and its subsequent downregulation in neutrophils. *J Cell Sci* 113(15):2737–2745
- Aullo P, Giry M, Olsnes S, Popoff MR, Kocks C, Boquet P (1993) A chimeric toxin to study the role of the 21 kDa GTP binding protein rho in the control of actin microfilament assembly. *EMBO J* 12:921–931
- Balboa MA, Insel PA (1995) Nuclear phospholipase D in Madin-Darby canine kidney cells—Guanosine 5'-O-(thiotriphosphate)-stimulated activation is mediated by RhoA and is downstream of protein kinase C. *J Biol Chem* 270:29843–29847
- Barbieri JT, Riese MJ, Aktories K (2002) Bacterial toxins that modify the actin cytoskeleton. *Annu Rev Cell Dev Biol* 18:315–344
- Barry ST, Flinn HM, Humphries MJ, Critchley DR, Ridley AJ (1997) Requirement for Rho in integrin signalling. *Cell Adhes Commun* 4:387–398
- Barth H, Hofmann F, Olenik C, Just I, Aktories K (1998) The N-terminal part of the enzyme component (C2I) of the binary *Clostridium botulinum* C2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. *Infect Immun* 66:1364–1369
- Barth H, Olenik C, Sehr P, Schmidt G, Aktories K, Meyer DK (1999) Neosynthesis and activation of Rho by *Escherichia coli* cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho. *J Biol Chem* 274:27407–27414
- Barth H, Blöcker D, Behlke J, Bergsma-Schutter W, Brisson A, Benz R, Aktories K (2000) Cellular uptake of *Clostridium botulinum* C2 toxin requires oligomerization and acidification. *J Biol Chem* 275:18704–18711
- Barth H, Blöcker D, Aktories K (2002) The uptake machinery of clostridial actin ADP-ribosylating toxins—a cell delivery system for fusion proteins and polypeptide drugs. *Naunyn-Schmiedeberg's Arch Pharmacol* 366:501–512
- Bayles KW, Wesson CA, Liou LE, Fox LK, Bohach GA, Trumble WR (1998) Intracellular *Staphylococcus aureus* escapes the endosome and induces apoptosis in epithelial cells. *Infect Immun* 66:336–342
- Bell CE, Eisenberg D (1996) Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. *Biochemistry* 35:1137–1149
- Bishop AL, Hall A (2000) Rho GTPases and their effector proteins. *Biochem J* 348:241–255
- Bobak DA (1999) Clostridial toxins: Molecular probes of Rho-dependent signaling and apoptosis. *Mol Cell Biochem* 193:37–42
- Böhmer J, Jung M, Sehr P, Fritz G, Popoff M, Just I, Aktories K (1996) Active site mutation of the C3-like ADP-ribosyltransferase from *Clostridium limosum*—analysis of glutamic acid 174. *Biochemistry* 35:282–289
- Boquet P, Munro P, Fiorentini C, Just I (1998) Toxins from anaerobic bacteria: specificity and molecular mechanisms of action. *Curr Opin Microbiol* 1:66–74

- Borrotto A, Gil D, Delgado P, Vicente-Manzanares M, Alcover A, Sanchez-Madrid F, Alarcon B (2000) Rho regulates T cell receptor ITAM-induced lymphocyte spreading in an integrin-independent manner. *Eur J Immunol* 30:3403–3410
- Braun U, Habermann B, Just I, Aktories K, Vandekerckhove J (1989) Purification of the 22 kDa protein substrate of botulinum ADP-ribosyltransferase C3 from porcine brain cytosol and its characterization as a GTP-binding protein highly homologous to the rho gene product. *FEBS Lett* 243:70–76
- Buhl AM, Johnson NL, Dhanasekaran N, Johnson GL (1995) $G\alpha_{12}$ and $G\alpha_{13}$ stimulate Rho-dependent stress fiber formation and focal adhesion assembly. *J Biol Chem* 270:24631–24634
- Burridge K, Wennerberg K (2004) Rho and Rac take center stage. *Cell* 116:167–179
- Caron E, Hall A (1998) Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. *Science* 282:1717–1721
- Chardin P, Boquet P, Madaule P, Popoff MR, Rubin EJ, Gill DM (1989) The mammalian G protein rho C is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilament in Vero cells. *EMBO J* 8:1087–1092
- Chen LY, Zuraw BL, Liu FT, Huang S, Pan ZK (2002) IL-1 receptor-associated kinase and low molecular weight GTPase RhoA signal molecules are required for bacterial lipopolysaccharide-induced cytokine gene transcription. *J Immunol* 169:3934–3939
- Choe S, Bennett MJ, Fujii G, Curmi PMG, Kantardjieff KA, Collier RJ, Eisenberg D (1992) The crystal structure of diphtheria toxin. *Nature* 357:216–222
- Chong LD, Traynor-Kaplan A, Bokoch GM, Schwartz MA (1994) The small GTP-binding protein Rho regulates a phosphatidylinositol 4-phosphate 5-kinase in mammalian cells. *Cell* 79:507–513
- Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L (2002) Rho signaling pathway targeted to promote spinal cord repair. *J Neurosci* 22:6570–6577
- Doussau F, Gasman S, Humeau Y, Vitiello F, Popoff M, Boquet P, Bader M-F, Poulain B (2000) A Rho-related GTPase is involved in Ca^{2+} -dependent neurotransmitter exocytosis. *J Biol Chem* 275:7764–7779
- Dreikhausen U, Varga G, Hofmann F, Barth H, Aktories K, Resch K, Szamel M (2001) Regulation by rho family GTPases of IL-1 receptor-induced signaling: C3-like chimeric toxin and Clostridium difficile toxin B inhibit signaling pathways involved in IL-2 gene expression. *Eur J Immunol* 31:1610–1619
- Dubreuil CI, Winton MJ, McKerracher L (2003) Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. *J Cell Biol* 162:233–243
- Eckhardt M, Barth H, Blöcker D, Aktories K (2000) Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. *J Biol Chem* 275:2328–2334
- Eda M, Yonemura S, Kato T, Watanabe N, Ishizaki T, Madaule P, Narumiya S (2001) Rho-dependent transfer of Citron-kinase to the cleavage furrow of dividing cells. *J Cell Sci* 114:3273–3284
- Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. *Nature* 420:629–635
- Evans HR, Sutton JM, Holloway DE, Ayriss J, Shone CC, Acharya KR (2003) The crystal structure of C3stau2 from Staphylococcus aureus and its complex with NAD. *J Biol Chem* 278:45924–45930
- Feig LA, Urano T, Cantor S (1996) Evidence for a Ras/Ral signaling cascade. *Trends Biochem Sci* 21:438–441
- Fiorentini C, Gauthier M, Donelli G, Boquet P (1998) Bacterial toxins and the Rho GTP-binding protein: what microbes teach us about cell regulation. *Cell Death Differ* 5:720–728
- Flatau G, Lemichez E, Gauthier M, Chardin P, Paris S, Fiorentini C, Boquet P (1997) Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. *Nature* 387:729–733
- Foster R, Hu K-Q, Lu Y, Nolan KM, Thissen J, Settleman J (1996) Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. *Mol Cell Biol* 16:2689–2699
- Fromm C, Coso OA, Montaner S, Xu N, Gutkind JS (1997) The small GTP-binding protein Rho links G protein-coupled receptors and $G\alpha_{12}$ to the serum response element and to cellular transformation. *Proc Natl Acad Sci* 94:10098–10103
- Fu Y, Galán JE (1999) A Salmonella protein antagonizes Rac-1 and Cdc42 to mediate host-cell recovery after bacterial invasion. *Nature* 401:293–297
- Fujihara H, Walker LA, Gong MC, Lemichez E, Boquet P, Somlyo AV, Somlyo AP (1997) Inhibition of RhoA translocation and calcium sensitization by in vivo ADP-ribosylation with the chimeric toxin DC3B. *Mol Biol Cell* 8:2437–2447
- Genth H, Gerhard R, Maeda A, Amano M, Kaibuchi K, Aktories K, Just I (2003a) Entrapment of Rho ADP-ribosylated by Clostridium botulinum C3 exoenzyme in the Rho-GDI-I complex. *J Biol Chem* 278:28523–28527
- Genth H, Schmidt M, Gerhard R, Aktories K, Just I (2003b) Activation of phospholipase D1 by ADP-ribosylated RhoA. *Biochem Biophys Res Commun* 302:127–132

- Goehring U-M, Schmidt G, Pederson KJ, Aktories K, Barbieri JT (1999) The N-terminal domain of *Pseudomonas aeruginosa* exoenzyme S is a GTPase-activating protein for Rho GTPases. *J Biol Chem* 274:36369–36372
- Gohla A, Schultz G, Offermanns S (2000) Role for G_{12}/G_{13} in agonist-induced vascular smooth muscle cell contraction. *Circ Res* 87:221–227
- Grunwald IC, Klein R (2002) Axon guidance: receptor complexes and signaling mechanisms. *Curr Opin Neurobiol* 12:250–259
- Guasch RM, Scambler P, Jones GE, Ridley AJ (1998) RhoE regulates actin cytoskeleton organization and cell migration. *Mol Cell Biol* 18:4761–4771
- Hall A (1994) Small GTP-binding proteins and the regulation of the actin cytoskeleton. *Annu Rev Cell Biol* 10:31–54
- Han S, Tainer JA (2002) The ARTT motif and a unified structural understanding of substrate recognition in ADP-ribosylating bacterial toxins and eukaryotic ADP-ribosyltransferases. *Int J Med Microbiol* 291:523–529
- Han S, Craig JA, Putnam CD, Carozzi NB, Tainer JA (1999) Evolution and mechanism from structures of an ADP-ribosylating toxin and NAD complex. *Nat Struct Biol* 6:932–936
- Han S, Arvai AS, Clancy SB, Tainer JA (2001) Crystal structure and novel recognition motif of Rho ADP-ribosylating C3 exoenzyme from *Clostridium botulinum*: Structural insights for recognition specificity and catalysis. *J Mol Biol* 305:95–107
- Hardt W-D, Chen L-M, Schuebel KE, Bustelo XR, Galán JE (1998) S. typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. *Cell* 93:815–826
- Heath JP, Holifield BF (1991) Cell locomotion: new research tests old ideas on membrane and cytoskeletal flow. *Cell Motil Cytoskeleton* 18:245–257
- Henning SW, Cantrell DA (1998) GTPases in antigen receptor signalling. *Curr Opin Immunol* 10:322–329
- Henning SW, Galandrini R, Hall A, Cantrell DA (1997) The GTPase Rho has a critical regulatory role in thymus development. *EMBO J* 16:2397–2407
- Hilal-Dandan R, Means CK, Gustafsson AB, Morissette MR, Adams JW, Brunton LL, Heller BJ (2004) Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho. *J Mol Cell Cardiol* 36:481–493
- Hill CS, Wynne J, Treisman R (1995) The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. *Cell* 81:1159–1170
- Hippenstiel S, Schmeck B, N'Guessan PD, Seybold J, Krüll M, Preissner K, Von Eichel-Streiber C, Suttrop N (2002) Rho protein inactivation induced apoptosis of cultured human endothelial cells. *Am J Physiol Lung Cell Mol Physiol* 283:L830–838
- Hoffmann C, Pop M, Leemhuis J, Schirmer J, Aktories K, Schmidt G (2004) The Yersinia pseudotuberculosis cytotoxic necrotizing factor (CNFY) selectively activates RhoA. *J Biol Chem* 279(16):16026–10632
- Inoue S, Sugai M, Murooka Y, Paik S-Y, Hong Y-M, Ohgai H, Suginaka H (1991) Molecular cloning and sequencing of the epidermal cell differentiation inhibitor gene from *Staphylococcus aureus*. *Biochem Biophys Res Commun* 174:459–464
- Jaffe AB, Hall A (2002) Rho GTPases in transformation and metastasis. *Adv Cancer Res* 84:57–80
- Jalink K, Van Corven EJ, Hengeveld T, Morii N, Narumiya S, Moolenaar WH (1994) Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. *J Cell Biol* 126:801–810
- Jiang H, Luo J-Q, Urano T, Frankel P, Lu Z, Foster DA, Feig LA (1995) Involvement of Ral GTPase in v-Src-induced phospholipase D activation. *Nature* 378:409–412
- Jullien-Flores V, Dorseuil O, Romero F, Letourneur F, Saragosti S, Berger R, Tavitian A, Gacon G, Camonis JH (1995) Bridging Ral GTPase to Rho pathways—RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. *J Biol Chem* 270:22473–22477
- Just I, Mohr C, Schallehn G, Menard L, Didsbury JR, Vandekerckhove J, van Damme J, Aktories K (1992) Purification and characterization of an ADP-ribosyltransferase produced by *Clostridium limosum*. *J Biol Chem* 267:10274–10280
- Just I, Selzer J, Jung M, van Damme J, Vandekerckhove J, Aktories K (1995a) Rho-ADP-ribosylating exoenzyme from *Bacillus cereus*—purification, characterization and identification of the NAD-binding site. *Biochemistry* 34:334–340
- Just I, Selzer J, Wilm M, Von Eichel-Streiber C, Mann M, Aktories K (1995b) Glucosylation of Rho proteins by *Clostridium difficile* toxin B. *Nature* 375:500–503
- Just I, Selzer J, Hofmann F, Green GA, Aktories K (1996) Inactivation of Ras by *Clostridium sordellii* lethal toxin-catalyzed glucosylation. *J Biol Chem* 271:10149–10153

- Just I, Hofmann F, Genth H, Gerhard R (2001) Bacterial protein toxins inhibiting low-molecular-mass GTP-binding proteins. *Int J Med Microbiol* 291:243–250
- Kanumilli S, Toms NJ, Venkateswarlu K, Mellor H, Roberts PJ (2002) Functional coupling of rat metabotropic glutamate 1a receptors to phospholipase D in CHO cells: involvement of extracellular Ca²⁺, protein kinase C, tyrosine kinase and Rho-A. *Neuropharmacology* 42:1–8
- Kato T, Watanabe N, Morishima Y, Fujita A, Ishizaki T, Narumiya S (2001) Localization of a mammalian homolog of diaphanous, mDia1, to the mitotic spindle in HeLa cells. *J Cell Sci* 114:775–784
- Klages B, Brandt U, Simon MI, Schultz G, Offermanns S (1999) Activation of G₁₂/G₁₃ results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. *J Cell Biol* 144:745–754
- Kozma R, Ahmed S, Best A, Lim L (1995) The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. *Mol Cell Biol* 15:1942–1952
- Kuribara H, Tago K, Yokozeki T, Sasaki T, Takai Y, Morii N, Narumiya S, Katada T, Kanaho Y (1995) Synergistic activation of rat brain phospholipase D by ADP-ribosylation factor and *rhoA* p21, and its inhibition by *Clostridium botulinum* C3 exoenzyme. *J Biol Chem* 270:25667–25671
- Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H (2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. *Cancer Res* 61:4885–4891
- Lamazé C, Chuang TH, Terlecky LJ, Bokoch GM, Schmid SL (1996) Regulation of receptor-mediated endocytosis by Rho and Rac. *Nature* 382:177–179
- Lang P, Guizani L, Vitté-Mony I, Stancou R, Dorseuil O, Gacon G, Bertoglio J (1992) ADP-ribosylation of the *ras*-related, GTP-binding protein RhoA inhibits lymphocyte-mediated cytotoxicity. *J Biol Chem* 267:11677–11680
- Laudanna C, Campbell JJ, Butcher EC (1996) Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. *Science* 271:981–983
- Laudanna C, Campbell JJ, Butcher EC (1997) Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. *J Biol Chem* 272:24141–24144
- Lehmann M, Fournier A, Selles-Navarro I, Dergham P, Sebock A, Leclerc N, Tigyi G, McKerracher, L (1999). Inactivation of Rho signaling pathway promotes CNS axon regeneration. *J Neurosci* 19:7537–7547
- Le Page SL, Bi Y, Williams JA (2003) CCK-A receptor activates RhoA through G alpha 12/13 in NIH3T3 cells. *Am J Physiol Cell Physiol* 285:C1197–C1206
- Li M, Dydá F, Benhar I, Pastan I, Davies DR (1996) Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: Implications for the activation process and for ADP ribosylation. *Proc Natl Acad Sci* 93:6902–6906
- Liberto M, Cobrinik D, Minden A (2002) Rho regulates p21(CIP1), cyclin D1, and checkpoint control in mammary epithelial cells. *Oncogene* 21:1590–1599
- Lowy FD (2000) Is *Staphylococcus aureus* an intracellular pathogen? *Trends Microbiol* 8:341–344
- Lu J, Landerholm TE, Wei JS, Dong XR, Wu SP, Liu X, Nagata K, Inagaki M, Majesky MW (2001) Coronary smooth muscle differentiation from proepicardial cells requires rhoA-mediated actin reorganization and p160 rho-kinase activity. *Dev Biol* 240:404–418
- Luo J-Q, Liu X, Frankel P, Rotunda T, Ramos M, Flom J, Jiang H, Feig LA, Morris AJ, Kahn RA, Foster DA (1998) Functional association between Arf and RalA in active phospholipase D complex. *Proc Natl Acad Sci* 95:3632–3637
- Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK (2001) Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. *J Biol Chem* 276:341–347
- Mackay DJG, Esch F, Furthmayr H, Hall A (1997) Rho- and Rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for Ezrin/radixin/Moesin proteins. *J Cell Biol* 138:927–938
- Maddala R, Deng PF, Costello JM, Wawrousek EF, Zigler JS, Rao VP (2004) Impaired cytoskeletal organization and membrane integrity in lens fibers of a Rho GTPase functional knockout transgenic mouse. *Lab Invest* 84:679–692
- Madden JC, Ruiz N, Caparon M (2001) Cytolysin-mediated translocation (CMT): a functional equivalent type III secretion in gram-positive bacteria. *Cell* 104:143–152
- Mao J, Yuan H, Xie W, Simon MI, Wu D (1998a) Specific involvement of G proteins in regulation of serum response factor-mediated gene transcription by different receptors. *J Biol Chem* 273:27118–27123

- Mao J, Yuan H, Xie W, Wu D (1998b) Guanine nucleotide exchange factor GEF115 specifically mediates activation of Rho and serum response factor by the G protein α subunit $G\alpha_{13}$. *Proc Natl Acad Sci* 95:12973–12976
- Marvaud JC, Stiles BG, Chenal A, Gillet D, Gibert M, Smith LA, Popoff MR (2002) *Clostridium perfringens* iota toxin. Mapping of the Ia domain involved in docking with Ib and cellular internalization. *J Biol Chem* 277:43659–43666
- Masuda M, Betancourt L, Matsuzawa T, Kashimoto T, Takao T, Shimonishi Y, Horiguchi Y (2000) Activation of Rho through a cross-link with polyamines catalyzed by *Bordetella* dermonecrotizing toxin. *EMBO J* 19:521–530
- Meacci E, Vasta V, Moorman JP, Bobak DA, Bruni P, Moss J, Vaughan M (1999) Effect of Rho and ADP-ribosylation factor GTPases on phospholipase D activity in intact human adenocarcinoma A549 cells. *J Biol Chem* 274:18605–18612
- Mempel M, Schnopp C, Hojka M, Fesq H, Weidinger S, Schaller M, Korting HC, Ring J, Abeck D (2002) Invasion of human keratinocytes by *Staphylococcus aureus* and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. *Br J Dermatol* 146:943–951
- Ménétreay J, Flatau G, Stura EA, Charbonnier J-B, Gas F, Teulon J-M, Le Du M-H, Boquet P, Ménez A (2002) NAD binding induces conformational changes in Rho ADP-ribosylating *Clostridium botulinum* C3 exoenzyme. *J Biol Chem* 277:30950–30957
- Meyer DK, Olenik C, Hofmann F, Barth H, Leemhuis J, Brünig I, Aktories K, Nörenberg W (2000) Regulation of somatodendritic GABA_A receptor channels in rat hippocampal neurons: Evidence for a role of the small GTPase Rac1. *J Neurosci* 20:6743–6751
- Mills JC, Stone NL, Erhardt J, Pittman RN (1998) Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. *J Cell Biol* 140:627–636
- Moskalenko S, Henry DO, Rosse C, Mirey G, Camonis JH, White MA (2001) The exocyst is a Ral effector complex. *Nat Cell Biol* 4:66–72
- Nagata K, Puls A, Futter C, Aspenstrom P, Schaefer E, Nakata T, Hirokawa N, Hall A (1998) The MAP kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3. *EMBO J* 17:149–158
- Narumiya S, Morii N (1993) *rho* gene products, botulinum C3 exoenzyme and cell adhesion. *Cell Signal* 5:9–19
- Nemoto E, Yu YJ, Dennert G (1996) Cell surface ADP-Ribosyltransferase regulates lymphocyte function-associated molecule-1 (LFA-1) function in T cells. *J Immunol* 157:3341–3349
- Nemoto Y, Namba T, Kozaki S, Narumiya S (1991) *Clostridium botulinum* C3 ADP-ribosyltransferase gene. *J Biol Chem* 266:19312–19319
- Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, Barde YA (2002) Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. *J Neurosci* 22:854–862
- Nguyen QD, Faivre S, Bruyneel E, Rivat C, Seto M, Endo T, Mareel M, Emami S, Gespach C (2002) RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. *FASEB J* 16:565–576
- Niederost B, Oertle T, Fritsche J, McKinney RA, Bandtlow CE (2002) Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. *J Neurosci* 22:10368–10376
- Nishiki T, Narumiya S, Morii N, Yamamoto M, Fujiwara M, Kamata Y, Sakaguchi G, Kozaki S (1990) ADP-ribosylation of the rho/rac proteins induces growth inhibition, neurite. *Biochem Biophys Res Commun* 167:265–272
- Nobes CD, Hall A (1995) Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. *Cell* 81:53–62
- Nobes CD, Lauritzen I, Mattei M-G, Paris S, Hall A, Chardin P (1998) A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. *J Cell Biol* 141:187–197
- Nusrat A, Giry M, Turner JR, Colgan SP, Parkos CA, Carnes D, Lemichez E, Boquet P, Madara JL (1995) Rho protein regulates tight junctions and perijunctional actin organization in polarized epithelia. *Proc Natl Acad Sci* 92:10629–10633
- O’Connell CB, Wheatley SP, Ahmed S, Wang YL (1999) The small GTP-binding protein Rho regulates cortical activities in cultured cells during division. *J Cell Biol* 144:305–313
- Ohishi I, Iwasaki M, Sakaguchi G (1980) Purification and characterization of two components of botulinum C2 toxin. *Infect Immun* 30:668–673

- Ohmori T, Yatomi Y, Okamoto H, Miura Y, Rile G, Satoh K, Ozaki Y (2001) G(i)-mediated Cas tyrosine phosphorylation in vascular endothelial cells stimulated with sphingosine 1-phosphate: possible involvement in cell motility enhancement in cooperation with Rho-mediated pathways. *J Biol Chem* 276:5274–5280
- Ohta Y, Suzuki N, Nakamura S, Hartwig JH, Stossel TP (1999) The small RalA targets filamin to induce filopodia. *Proc Natl Acad Sci* 96:2122–2128
- Olson MF, Ashworth A, Hall A (1995) An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G₁. *Science* 269:1270–1272
- Oppenheimer NJ (1994) NAD hydrolysis: Chemical and enzymatic mechanisms. *Mol Cell Biochem* 138:245–251
- Park J, Kim JS, Jung KC, Lee HJ, Kim JI, Kim J, Lee JY, Park JB, Choi SY (2003) Exoenzyme Tat-C3 inhibits association of zymosan particles, phagocytosis, adhesion, and complement binding in macrophage cells. *Mol Cell* 16:216–223
- Park SH, Weinberg RA (1995) A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. *Oncogene* 11:2349–2355
- Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A (1990) Microinjection of recombinant p21^{rho} induces rapid changes in cell morphology. *J Cell Biol* 111:1001–1007
- Popoff MR, Boquet P, Gill DM, Eklund MW (1990) DNA sequence of exoenzyme C3, an ADP-ribosyltransferase encoded by *Clostridium botulinum* C and D phages. *Nucleic Acids Res* 18:1291–1291
- Prepens U, Just I, Von Eichel-Streiber C, Aktories K (1996) Inhibition of FcεRI-mediated activation of rat basophilic leukemia cells by *Clostridium difficile* toxin B (monoglucosyltransferase). *J Biol Chem* 271:7324–7329
- Price LS, Norman JC, Ridley AJ, Koffer A (1995) The small GTPases Rac and Rho as regulators of secretion in mast cells. *Curr Biol* 5:68–73
- Quilliam LA, Lacal J-C, Bokoch GM (1989) Identification of rho as a substrate for botulinum toxin C3-catalyzed ADP-ribosylation. *FEBS Lett* 247:221–226
- Rao V, Wawrousek E, Tamm ER, Zigler S Jr (2002) Rho GTPase inactivation impairs lens growth and integrity. *Lab Invest* 82:231–239
- Ren X-D, Bokoch GM, Traynor-Kaplan A, Jenkins GH, Anderson RA, Schwartz MA (1996) Physical association of the small GTPase Rho with a 68-kDa phosphatidylinositol 4-phosphate 5-kinase in swiss 3T3 cells. *Mol Biol Cell* 7:435–442
- Reuveny M, Heller H, Bengal E (2004) RhoA controls myoblast survival by inducing the phosphatidylinositol 3-kinase-Akt signaling pathway. *FEBS Lett* 569:129–134
- Ridley A (2000) Rho. In: Hall A, (ed) GTPases. Oxford University Press, Oxford, pp. 89–136
- Ridley AJ, Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. *Cell* 70:389–399
- Ridley AJ, Hall A (2004) Snails, Swiss, and serum: the solution for Rac 'n' Rho. *Cell* 116:S23–5, 2
- Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. *Cell* 70:401–410
- Riento K, Guasch RM, Garg R, Jin B, Ridley AJ (2003) RhoE binds to ROCK I and inhibits downstream signaling. *Mol Cell Biol* 23:4219–4229
- Rubin EJ, Gill DM, Boquet P, Popoff MR (1988) Functional modification of a 21-Kilodalton G protein when ADP-ribosylated by exoenzyme C3 of *Clostridium botulinum*. *Mol Cell Biol* 8:418–426
- Sagi SA, Seasholtz TM, Kobiasvili M, Wilson BA, Toksoz D, Brown JH (2001) Physical and functional interactions of Galphaq with Rho and its exchange factors. *J Biol Chem* 276:15445–15452
- Sah VP, Hoshijima M, Chien KR, Brown JH (1996) Rho is required for Gα_q and α₁-adrenergic receptor signaling in cardiomyocytes—dissociation of Ras and Rho pathways. *J Biol Chem* 271:31185–31190
- Sah VP, Seasholtz TM, Sagi SA, Brown JH (2000) The role of Rho in G protein-coupled receptor signal transduction. *Annu Rev Pharmacol Toxicol* 40:459–489
- Sahai E, Alberts AS, Treisman R (1998) RhoA effector mutants reveal distinct effector pathways for cytoskeletal reorganization, SRF activation, and transformation. *EMBO J* 17:1350–1361
- Saito Y, Nemoto Y, Ishizaki T, Watanabe N, Morii N, Narumiya S (1995) Identification of Glu¹⁷³ as the critical amino acid residue for the ADP-ribosyltransferase activity of *Clostridium botulinum* C3 exoenzyme. *FEBS Lett* 371:105–109
- Santos MF, McCormack SA, Guo Z, Okolicany J, Zheng Y, Johnson LR, Tigyi G (1997) Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. *J Clin Invest* 100:216–225
- Saurin JC, Fallavier M, Sordat B, Gévrey JC, Chayvialle JA, Abello J (2002) Bombesin stimulates invasion and migration of Isrecol colon carcinoma cells in a Rho-dependent manner. *Cancer Res* 62:4829–4835

- Sauzeau V, Le Mellionec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G (2001) Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. *Circ Res* 88:1102–1104
- Schmalzing G, Richter HP, Hansen A, Schwarz W, Just I, Aktories K (1995) Involvement of the GTP binding protein Rho in constitutive endocytosis in *Xenopus laevis* oocytes. *J Cell Biol* 130:1319–1332
- Schmidt G, Sehr P, Wilm M, Selzer J, Mann M, Aktories K (1997) Gln63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor 1. *Nature* 387:725–729
- Schmidt M, Rümennapp U, Bienek C, Keller J, Von Eichel-Streiber C, Jakobs KH (1996) Inhibition of receptor signaling to phospholipase D by *Clostridium difficile* toxin B—role of Rho proteins. *J Biol Chem* 271:2422–2426
- Schmidt M, Voss M, Weernink PA, Wetzel J, Amano M, Kaibuchi K, Jakobs KH (1999) A role for Rho-kinase in Rho-controlled phospholipase D stimulation by the m3 muscarinic acetylcholine receptor. *J Biol Chem* 274:14648–14654
- Sehr P, Joseph G, Genth H, Just I, Pick E, Aktories K (1998) Glucosylation and ADP-ribosylation of Rho proteins—effects on nucleotide binding, GTPase activity, and effector-coupling. *Biochemistry* 37:5296–5304
- Sekine A, Fujiwara M, Narumiya S (1989) Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. *J Biol Chem* 264:8602–8605
- Selzer J, Hofmann F, Rex G, Wilm M, Mann M, Just I, Aktories K (1996) *Clostridium novyi* α -toxin-catalyzed incorporation of GlcNAc into Rho subfamily proteins. *J Biol Chem* 271:25173–25177
- Shao F, Merritt PM, Bao Z, Innes RW, Dixon JE (2002) A *Yersinia* effector and a *Pseudomonas* avirulence protein define a family of cysteine proteases functioning in bacterial pathogenesis. *Cell* 109:575–588
- Shao F, Vacratsis PO, Bao Z, Bowers KE, Fierke CA, Dixon JE (2003) Biochemical characterization of the *Yersinia* YopT protease: Cleavage site and recognition elements in Rho GTPases. *Proc Natl Acad Sci* 100:904–909
- Sotiropoulos A, Gineitis D, Copeland J, Treisman R (1999) Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. *Cell* 98:159–169
- Stam JC, Michiels F, Van der Kammen RA, Moolenaar WH, Collard JG (1998) Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. *EMBO J* 17:4066–4074
- Strey A, Janning A, Barth H, Gerke V (2002) Endothelial Rho signaling is required for monocyte transendothelial migration. *FEBS Lett* 517:261–266
- Su LF, Knoblauch R, Garabedian MJ (2001) Rho GTPases as modulators of the estrogen receptor transcriptional response. *J Biol Chem* 276:3231–3237
- Sugai M, Hashimoto K, Kikuchi A, Inoue S, Okumura H, Matsumoto K, Goto Y, Ohgai H, Moriishi K, Syuto B, Yoshikawa K, Suginaka H, Takai Y (1992) Epidermal cell differentiation inhibitor ADP-ribosylates small GTP-binding proteins and induces hyperplasia of epidermis. *J Biol Chem* 267:2600–2604
- Takaishi K, Sasaki T, Kato M, Yamochi W, Kuroda S, Nakamura T, Takeichi M, Takai Y (1994) Involvement of *Rho* p21 small GTP-binding protein and its regulator in the HGF-induced cell motility. *Oncogene* 9:273–279
- Takaishi K, Sasaki T, Kameyama T, Tsukita S, Takai Y (1995) Translocation of activated *Rho* from the cytoplasm to membrane ruffling area, cell-cell adhesion sites and cleavage furrows. *Oncogene* 11:39–48
- Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK (2002) Rho-kinase mediates hypoxia-induced down-regulation of endothelial nitric oxide synthase. *Circulation* 106:57–62
- Tigyi G, Fischer DJ, Sebök A, Yang C, Dyer DL, Miledi R (1996) Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca²⁺ signaling and Rho. *J Neurochem* 66:537–548
- Urano T, Emkey R, Feig LA (1996) Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. *EMBO J* 15:810–816
- Valderrama F, Luna A, Babia T, Martinez-Menarguez JA, Ballesta J, Barth H, Chaponnier C, Renau-Piqueras J, Egea G (2000) The golgi-associated COPI-coated buds and vesicles contain beta/gamma-actin. *Proc Natl Acad Sci* 97:1560–1565
- Verschuere H, De Baetselier P, De Braekeleer J, Dewit J, Aktories K, Just I (1997) ADP-ribosylation of Rho-proteins with botulinum C3 coenzyme inhibits invasion and shape changes of T-lymphoma cells. *Eur J Cell Biol* 73:182–187
- Vischer UM, Barth H, Wollheim CB (2000) Regulated von willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. *Arterioscler Thromb Vasc Biol* 20:883–891

- Vögler O, Krummenerl P, Schmidt M, Jakobs KH, van Koppen CJ (1999) RhoA-sensitive trafficking of muscarinic acetylcholine receptors. *J Pharmacol Exp Ther* 288:36–42
- von Pawel-Rammingen U, Telepnev MV, Schmidt G, Aktories K, Wolf-Watz H, Rosqvist R (2000) GAP activity of the *Yersinia* YopE cytotoxin specifically targets the Rho pathway: a mechanism for disruption of actin microfilament structure. *Mol Microbiol* 36:737–748
- Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E (1998) Regulation of the actin cytoskeleton by thrombin in human endothelial cells: Role of Rho proteins in endothelial barrier function. *Mol Biol Cell* 9:2639–2653
- Wahl S, Barth H, Ciossek T, Aktories K, Mueller BK (2000) Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. *J Cell Biol* 149:263–270
- Watanabe N, Madaule P, Reid T, Ishizaki T, Watanabe G, Kakizuka A, Saito Y, Nakao K, Jockusch BM, Naumiya S (1997) p140mDia, a mammalian homolog of *Drosophila* diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. *EMBO J* 16:3044–3056
- Weernink PA, Guo Y, Zhang C, Schmidt M, Von Eichel-Streiber C, Jakobs KH (2000) Control of cellular phosphatidylinositol 4,5-bisphosphate levels by adhesion signals and Rho GTPases in NIH 3T3 fibroblasts involvement of both phosphatidylinositol-4-phosphate and phospholipase C. *Eur J Biochem* 267:5237–5246
- Wennerberg K, Der CJ (2004) Rho-family GTPases: it's not only Rac and Rho (and I like it). *J Cell Sci* 117:1301–1312
- Wiegiers W, Just I, Müller H, Hellwig A, Traub P, Aktories K (1991) Alteration of the cytoskeleton of mammalian cells cultured in vitro by Clostridium botulinum C2 toxin and C3 ADP-ribosyltransferase. *Eur J Cell Biol* 54:237–245
- Wilde C, Aktories K (2001) The Rho-ADP-ribosylating C3 exoenzyme from Clostridium botulinum and related C3-like transferases. *Toxicon* 39:1647–1660
- Wilde C, Chhatwal GS, Aktories K (2001a) C3stau, a new member of the family of C3-like ADP-ribosyltransferases. *Trends Microbiol* 10:5–7
- Wilde C, Chhatwal GS, Schmalzing G, Aktories K, Just I (2001b) A novel C3-like ADP-ribosyltransferase from *Staphylococcus aureus* modifying RhoE and Rnd3. *J Biol Chem* 276:9537–9542
- Wilde C, Barth H, Sehr P, Han L, Schmidt M, Just I, Aktories K (2002a) Interaction of the Rho-ADP-ribosylating C3 exoenzyme with RalA. *J Biol Chem* 277:14771–14776
- Wilde C, Just I, Aktories K (2002b) Structure-function analysis of the Rho-ADP-ribosylating exoenzyme C3stau2 from *Staphylococcus aureus*. *Biochemistry* 41:1539–1544
- Wilde C, Vogelsang M, Aktories K (2003) Rho-specific *Bacillus cereus* ADP-ribosyltransferase C3cer cloning and characterization. *Biochemistry* 42:9694–9702
- Winton MJ, Dubreuil CI, Lasko D, Leclerc N, McKerracher L (2002) Characterization of new cell permeable C3-like proteins that inactivate Rho and stimulate neurite outgrowth on inhibitory substrates. *J Biol Chem* 277:32820–32829
- Wojciak-Stothard B, Entwistle A, Garg R, Ridley AJ (1998) Regulation of TNF- α -induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. *J Cell Physiol* 176:150–165
- Worthylake RA, Lemoine S, Watson JM, BurrIDGE K (2001) RhoA is required for monocyte tail retraction during transendothelial migration. *J Cell Biol* 154:147–160
- Xie Z, Ho WT, Spellman R, Cai S, Exton JH (2002) Mechanisms of regulation of phospholipase D1 and D2 by the heterotrimeric G proteins G13 and Gq. *J Biol Chem* 277:11979–11986
- Yamaguchi T, Hayashi T, Takami H, Ohnishi M, Murata T, Nakayama K, Asakawa K, Ohara M, Komatsuzawa H, Sugai M (2001) Complete nucleotide sequence of a *Staphylococcus aureus* exfoliative toxin B plasmid and identification of a novel ADP-ribosyltransferase, EDIN-C. *Infect Immun* 69:7760–7771
- Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T (2000) Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. *Hypertension* 35:313–318
- Yoshioka K, Matsumura F, Akedo H, Itoh K (1998) Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. *J Biol Chem* 273:5146–5154
- Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, Duan S (2003) Signalling and crosstalk of Rho GTPases in mediating axon guidance. *Nat Cell Biol* 5:38–45